---
document_datetime: 2024-09-23 11:47:10
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/kayfanda-epar-all-authorised-presentations_en.pdf
document_name: kayfanda-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8497012
conversion_datetime: 2025-12-28 14:21:57.74163
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/24/1854/001 | Kayfanda          | 200 µg     | Capsule, hard         | Oral use                  | bottle (HDPE)         | 30 capsules |
| EU/1/24/1854/002 | Kayfanda          | 400 µg     | Capsule, hard         | Oral use                  | bottle (HDPE)         | 30 capsules |
| EU/1/24/1854/003 | Kayfanda          | 600 µg     | Capsule, hard         | Oral use                  | bottle (HDPE)         | 30 capsules |
| EU/1/24/1854/004 | Kayfanda          | 1200 µg    | Capsule, hard         | Oral use                  | bottle (HDPE)         | 30 capsules |